Browsing by Author "Pavlovic, A.M. (7003808508)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Increased total homocysteine level is associated with clinical status and severity of white matter changes in symptomatic patients with subcortical small vessel disease(2011) ;Pavlovic, A.M. (7003808508) ;Pekmezovic, T. (7003989932) ;Obrenovic, R. (56199010700) ;Novakovic, I. (6603235567) ;Tomic, G. (24831368600) ;Mijajlovic, M. (55404306300)Sternic, N. (6603691178)Objective: Elevated plasma total homocysteine (tHcy) is an independent risk factor for ischemic stroke and has been linked to cerebral small vessel disease (SVD), in particular. Controversy persists as to whether increased tHcy is associated with functional status and cognitive decline in these patients. Methods: Plasma tHcy, MTHFR polymorphism, vascular risk factors, functional and cognitive status and severity of lesions on MRI, assessed with the Age-Related White Matter Changes (ARWMC) visual grading scale, were analyzed in 95 patients with SVD and 41 healthy control subjects. Results: Plasma tHcy levels were higher in patients with SVD (14.4 ± 5.0 μmol/L) compared to healthy SVD-free controls (8.9 ± 3.9 μmol/L). In SVD patients, tHcy levels strongly correlated with cognitive status (age-adjusted risk 5.8, 95% CI 1.3-25.3, p = 0.015), functional status (age-adjusted risk 3.2, 95% CI 1.2-8.8, p = 0.022) and severity of MRI lesions (age-adjusted risk 1.2, 95% CI 1.1-1.4; p = 0.004). Only total ARWMC score was independently associated with increased tHcy levels (OR 1.2, 95%CI 1.1-1.4, p = 0.004). Independent predictors of WMC occurrence were tHcy levels (OR 1.2, 95%CI 1.1-1.3, p = 0.003) and mRS score (OR 2.2, 95%CI 1.2-4.1, p = 0.017). Conclusions: In patients with cerebral SVD there is a positive association of increased plasma tHcy levels with clinical status and severity of WMC. © 2011 Elsevier B.V. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency(2012) ;Pavlovic, A.M. (7003808508) ;Bonaci-Nikolic, B. (10839652200) ;Kozic, D. (6602538657) ;Ostojic, J. (12797904900) ;Abinun, M. (55880862200) ;Svabic-Medjedovic, T. (54783513300) ;Nikolic, M. (56910382000)Sternic, N. (6603691178)There is an increase in the number of patients with systemic lupus erythematosus (SLE) reported as developing progressive multifocal leukoencephalopathy (PML) while on intensive immunosuppressive therapy. A 39-year-old HIV-negative woman with a 10-year history of SLE presented with progressive left-side weakness while on maintenance therapy with oral prednisone and mycophenolate mofetil (MMF). On several occasions low CD4+ T-lymphocyte counts were found (68/μL). Brain magnetic resonance imaging (MRI) revealed a large lesion in the right subcortical fronto-parietal region and a smaller one in the left frontal subcortex, corresponding to the PML. In cerebrospinal fluid, polymerase chain reaction (PCR) for JC virus (JCV) was negative, but anti-JCV antibodies were highly positive. Diagnosis of probable PML was made and MMF was withdrawn. The patient's condition improved with marked reduction of left-side weakness and an increase in CD4+ T-lymphocyte count (141/μL). Follow-up MRI showed regression of lesions and over the next 6 months the patient remained stable. In spite of the grave prognosis associated with PML, SLE patients can have an excellent outcome if immunosuppressants are discontinued as soon as the correct diagnosis is made. SLE patients with associated low CD4+ T-lymphocyte counts should be monitored for the development of PML during immunosuppressive therapy in particular. © The Author(s), 2011.
